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Background:Diagnosis of apical HCMutilizes conventionalwall thickness criteria. The normal left ventricularwall
thins towards the apex such that normal values are lower in the apical versus the basal segments. The impact of
this on the diagnosis of apical hypertrophic cardiomyopathy has not been evaluated.
Methods: We performed a retrospective review of 2662 consecutive CMR referrals, of which 75 patients were
identiﬁed in whom there was abnormal T-wave inversion on ECG and a clinical suspicion of hypertrophic
cardiomyopathy. These were retrospectively analyzed for imaging features consistent with cardiomyopathy,
speciﬁcally: relative apical hypertrophy, left atrial dilatation, scar, apical cavity obliteration or apical aneurysm.
For comparison, the same evaluation was performed in 60 healthy volunteers and 50 hypertensive patients.
Results: Of the 75 patients, 48 met conventional HCM diagnostic criteria and went on to act as another compar-
ator group. Twenty-seven did not meet criteria for HCM and of these 5 had no relative apical hypertrophy and
were not analyzed further. The remaining 22 patients had relative apical thickening with an apical:basal wall
thickness ratio N1 and a higher prevalence of features consistent with a cardiomyopathy than in the control
groups with 54% having 2 or more of the 4 features. No individual in the healthy volunteer group had more
than one feature and no hypertension patient had more than 2.
Conclusion: A cohort of individuals exist with T wave inversion, relative apical hypertrophy and additional imag-
ing features of HCM suggesting an apical HCM phenotype not captured by existing diagnostic criteria.© 2015 Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. What is already known about this subject?
There are a signiﬁcant number of patients where conventional in-
vestigation with ECG and echocardiography fails to reach a diagnosis
butwhere CMR can diagnose hypertrophic cardiomyopathy. This occurs
most frequently in a subtype: apical hypertrophic cardiomyopathy —
where these patients are known to be at equal risk from the underlying
disease. Despite this, there are many patients where conventional
criteria fail to make a diagnosis despite clinical suspicion.e reliability and freedom from
ion.
Westmoreland Street, London
cess article under the CC BY license (2. What does this study add?
This study implies that a prephenotypic variant of HCM exists with
extensive T wave inversion on ECG and relative but not absolute apical
hypertrophy. These features are best seen using cardiovascular magnet-
ic resonance imaging which can identify patients with disease features
who could otherwise be labeled as normal but who may share their
fate with patients who have overt HCM. Further study of these patients
is needed to track associated morbidity and prognosis.
3. Howmight this impact on clinical practice?
We have identiﬁed a group of patients with a distinct phenotype
not captured by existing disease classiﬁcations. These share the
characteristics of patients with classical apical hypertrophic cardiomy-
opathy (HCM). With the criteria outlined in this article, patients canhttp://creativecommons.org/licenses/by/4.0/).
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screening.4. Introduction
There are patients who present with ECG changes and symptoms
that suggest hypertrophic cardiomyopathy (HCM), yet ﬁndings on
echocardiography are non-diagnostic. Some of these patients are identi-
ﬁed using cardiovascularmagnetic resonance (CMR) as havingHCMbut
with hypertrophy conﬁned to the apex [1,2]. With the increasing use of
CMR to accurately deﬁne cardiac anatomy in HCM [3–5], we have noted
another group of patients with the same ECG changes but where HCM
diagnostic criteria [6–8] (left ventricular wall thickness over 15 mm)
are not fulﬁlled and yet the apex is abnormal with relative rather than
absolute apical hypertrophy. These patients often have other imaging
abnormalities more commonly observed in HCM patients such as aFig. 1. a, Case in point 1 (see online supplementary cine images). An athletic 49 year oldmanwi
abnormal ECG (deep infero-lateral TWI, a) and a normal echocardiogram for CMR. This demon
14mm tube-like apical cavity (arrowed, b, c)which obliterates in systole; 3) a small apicalmicr
dilatation (e). This patient was subsequently found to have a genemutation in myosin binding
and right images; all images are indiastole (SSFP cine stills). Top row4 chamber, bottom row2 c
whichwas related to gall stone disease.Maximumwall thickness in 2008was 12mmwith apica
18 mm with apical cavity obliteration of 41 mm. He now has a formal diagnosis of HCM.dilated left atrium, systolic apical cavity obliteration, scar identiﬁed on
CMR, and apical microaneurysm. See cases in point, Fig. 1.
We hypothesized that individuals with T-wave inversion (TWI)
would share similar disease characteristics as seen in HCM and
sought to deﬁne these characteristics compared to health, established




An ethics committee of the UK National Research Ethics Service ap-
proved generic, retrospective analysis of anonymized clinical scans. All
research was carried out at University College London Hospital NHS
Trust, London between October 2008 and June 2010, where a tertiary
referral center for both cardiomyopathy and CMR exists. A retrospectiveth no family history and normal coronary arteries was referredwith atypical chest pain, an
strated: 1) a discrete increase in wall thickness at the apex (10 mm vs 8 mm basally); 2) a
o-aneurysm un-obliterated in systole (arrowed, f); 4) apical scar (arrows d, g). 5) Left atrial
protein C3 (R810H). b, Case in point 2. Despite the different appearances between the left
hamber. Left: Index scan2008of 47 year oldmale referredwith TWI andatypical chest pain
l cavity obliteration of 25mm. At follow-up 6 years later, themaximumwall thicknesswas
Fig. 2.Measuring apical wall thickness. Left: short axis slice near the base of the heart with
max wall thickness of 8 mm. Middle: four chamber view. The left ventricle is divided into
thirds: Basal, mid and apical, the apical cap makes up only the most apical 6% of the ven-
tricle. At the base the short axis slice is truly perpendicular to the wall. Towards the distal
ventricle— as the cavity tapers, the short axis slice is not perpendicular to the wall— this
complicateswall thicknessmeasurement and it should be performedonmultiple long axis
views, perpendicular to the true septal axis andwith careful exclusion of papillary muscle
origins and trabeculation.
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was performed. We identiﬁed 75 patients referred with unexplained
T-Wave inversion (TWI) and clinical suspicion of hypertrophic cardio-
myopathy. Sixty healthy control volunteers and ﬁfty hypertensive pa-
tients were studied as comparator populations. The volunteers were
recruited from the hospital staff, the university, a local general practice
and a dance class. All underwent a cardiac history, ECG, blood pressure
measurement and contrast CMRwith no abnormalities detected. Family
history of HCM (ﬁrst degree relative) was obtained from the clinical
notes and by telephone interview at the time of analysis. The hyperten-
sive controls (consecutive consenting hypertension patients from a
dedicated tertiary care hypertension service with clinic BP N 140/90)
underwent ECG and contrast CMR.
Standard 12 lead ECG was obtained in all patients and volunteers
The ECGwas analyzed for the presence, location, depth and distribution
of T-wave inversion in the anterior leads. The presence of T-wave inver-
sion was deﬁned when it extended beyond lead V2, deep TWI was de-
ﬁned as greater than or equal to 5 mm.
5.2. CMR acquisition and analysis
Standard CMR examinationwas performed in all patients [9] on a 1.5
T scanner (Avanto, Siemens, Erlangen, Germany). Appropriate methods
were used to optimize image quality. Where conventional long axisTable 1
Patient and control subject characteristics.
Disease candidate (n = 22) HC
Age 50 ± 15 56
Male gender n (%) 13 (60%) 41
% White/Asian/Black 82/5/13 60/
%TWI/deep TWI 27/73 21/
EDV (ml) 128 ± 31 117
ESV (ml) 31 ± 16 25
SV (ml) 98 ± 21 92
EF (%) 76 ± 8 79
Mass (g) 156 ± 40 223
Left atrial area (cm2) 28 ± 7 27
Max WT base (mm) 10 ± 1 14
Max WT apex (mm) 12 ± 1 17
Cavity oblit (mm) 23 ± 10 39
MAPSE (mm) 12 ± 3 11
Number of antihypertensives. (0/1/2/3/4/5/6)
a Unpaired T-Test vs disease candidate patients.views suggested apical abnormalities, additional 5 mm (rather than
conventional 7 mm) slices and cross cuts were made (as per our stan-
dard practice). For scar imaging, contrast (0.1 mmol/kg, Dotarem —
Guerbet, S.A.) was administrated intravenously and standard breath-
hold, inversion recovery imaging was performed. Additional conﬁrma-
tory views for scar were performed where necessary (phase swaps,
SSFP read-out, imaging in systole) [9–11]. Myocardial volumes and
mass analyses were carried out using standard techniques [9].
5.3. Deﬁnitions
Hypertrophy — apical or elsewhere — was deﬁned as a compacted
myocardial wall thickness in diastole greater than or equal to 14 mm,
with meticulous exclusion of overlying LV/RV trabeculae (assessed on
cine images). Fourteen millimeters (rather than conventional echocar-
diography thickness of 15 mm) was used as the threshold since CMR
measures wall thickness thinner than echocardiography in the basal
septal segments [5]. For apical hypertrophy where measurement is po-
tentially fraught, extra care and attention to detail was used. Measure-
ment was performed on the three long axis views using the 7 and/or
5 mm crosscuts and where the imaging plane was not foreshortening
the ventricle, visualizing the true cardiac apex (but not the apical cap).
In choosing where to measure (septal, anterior, inferior or lateral) the
short axis views were consulted and the base of papillary muscles and
trabeculae were carefully avoided. Measurement was performed per-
pendicular to the axis of the wall and at the point of maximal thickness
(see Fig. 2).
Relative apical hypertrophy was deﬁned as the absence of
hypertrophy (wall thickness b 14 mm) but with the apical wall thick-
ness greater than the basal wall thickness (apex:base ratio (ABR) wall
thickness N 1).
Additional imaging disease features of HCMwere deﬁned as follows:
1. Systolic anterior motion of the mitral valve ascertained using frame
by frame analysis in the three chamber view and or supporting
basal short axis view(s).
2. Mitral annular planar systolic excursion (MAPSE) measured using
standard techniques and deﬁned for this analysis as abnormal
when b10 mm.
3. Left atrial dilatation, deﬁned in the 4 chamber view with an upper
limit of 25 cm2 [12].
4. Abnormal systolic apical cavity obliteration was graded as N20 mm
or N10 mm. Measured in the 5 mm long axis cine crosscuts in the 3
views (4ch, 2ch, LVOT view) from the apical cap to the blood cavity





± 11 0.10 55 ± 15 0.56 53 ± 17 0.78
(85%) 0.001 32 (64%) 0.56 35 (59%) 0.89
23/17 b0.001 66/18/16 0.009 90/8/2 0.01
79 n/a 0/0 n/a 0/0 n/a
± 24 0.09 144 ± 42 b0.001 133 ± 31 0.007
± 10 0.06 47 ± 26 b0.001 44 ± 14 b0.001
± 20 0.26 96 ± 24 0.32 89 ± 20 0.36
± 7 0.23 69 ± 11 b0.001 68 ± 5 b0.001
± 69 b0.001a 163 ± 64 0.01 123 ± 33 b0.001
± 6 0.43 23 ± 4 b0.001 20 ± 4 b0.001
± 4 b0.001a 11 ± 3 0.05 8 ± 1 b0.001
± 4 b0.001a 6 ± 2 b0.001 5 ± 1 b0.001
± 15 b0.001a 8 ± 5 b0.001 4 ± 3 b0.001
± 2 0.10 12 ± 3 0.10 13 ± 2 b0.001
7/5/13/7/4/3/1
Fig. 3.Graph showing number of abnormal criteria fulﬁlled by disease type. This illustrates
that there aremany patients in the relative apical hypertrophy groupwho aremuchmore
akin to true HCM than to normal but there is considerable overlap.
Table 2
Results.
HCM (n = 48) Disease candidate (n = 22) Hypertensive controls (n = 50) Healthy controls (n = 60)
Relative apical hypertrophy 36 (75%) 22 (100%) 0 0
Apex:base wall thickness ratio 1.2 ± 0.3 1.2 ± 0.1 0.5 ± 0.1 0.6 ± 0.1
LA dilated ≥ 25 mm 34 (71%) 15 (68%) 17 (34%) 8 (13%)
Apical obliteration
N10 mm 47 (98%) 21 (95%) 10 (20%) 0
N20 mm 40 (83%) 14 (64%) 0 0
Apical microaneurysm 11 (23%) 3 (14%) 0 0
Scar 33 (67%) 9 (41%) 4 (8%) 0
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distal to cavity obliteration in systole.
6. Scar by LGEwas deﬁned visually by 2 independent observers and de-
ﬁned as present or absent.
5.4. Statistics
Data are expressed as mean+/− standard deviation or median and
interquartile range (for normal and non-normally distributed data re-
spectively). Groupmeans comparisons were performed using Student's
T-test (two groups) given that the a priori hypothesis was that each pa-
tient group would differ from health. Chi square test was used to com-
pare frequency of categorical data. A p b 0.05 was considered
statistically signiﬁcant. SPSS [13] Version 17was used for analysis. Anal-
yses were performed in a blinded fashion.
6. Results
Of the 75 patients coronary angiography had been performed in 35
of which 18 had normal coronary arteries, 15 had minor atheroma, 2
had undergone angioplasty (1 left anterior descending artery and 1 to
circumﬂex) — but without sustained symptomatic/ECG improvement
such that alternative diagnoses were sought. Forty had not undergone
angiography (of which four had a normal perfusion scan).
Patient and comparator group characteristics are presented in
Table 1. All CMR scans were of adequate image quality.
Of the 75 patients, 48met conventional HCMcriteria (43weremales
with a mean ± SD age of 56 ± 11 years). Of the remaining 27, 22 had
relative apical hypertrophy (ABR N 1, 5 other patients with ABR b 1
were not studied further). These 22 patients are the disease candidate
group and form the group studied from here on. Of these 22 patients
the mean age was 50 ± 15, 9 were females, 18 Caucasian, 3 Black, and
1 Asian. Eight had a documented family history of HCM. One patient
had a history of syncope and 5 had non sustained ventricular tachycar-
dia recorded on Holter monitoring. No patient in this group had aortic
stenosis or coarctation; 6 patients had a history of mild hypertension
(on ≤2 antihypertensive agents). Nine had LGE (7 limited to the apex,
two had mid-myocardial scar in the area of maximum hypertrophy).
They all had TWI (by deﬁnition) and 16 (73%) had deep TWI. None of
the healthy and hypertensive control groups had TWI. The mean apical
wall thickness and ABR was signiﬁcantly greater in the patients with
TWI (1.2 ± 0.1) than in healthy volunteers and hypertensive patients
(Table 2 and Fig. 3). No healthy individual had an ABR of N0.9 and no
hypertensive N 0.7 ie. the apical WT was universally thinner than the
base. In fact the mean ABR was signiﬁcantly lower in hypertension
than in controls (0.6±0.1mmvs 0.5±0.1mm, p b 0.001) even though
themeanbasalwall thicknesswas greater (11±0.1mmvs 8±0.1mm,
p b 0.001). The pattern of LGE in the hypertension group (present in 4
patients)wasmid-myocardial and limited to the right ventricular inser-
tion points. Of the 6 additional putative disease features (left atrial dila-
tation,MAPSE b 10mm, apical cavity obliteration, apical aneurysm, scar
by LGE, or systolic anterior motion of the mitral valve) two were not
considered in the analysis: SAM because it occurred in only one case
and MAPSE b 10 mm because it was not worse in the candidate diseasepopulation compared to hypertension and healthy controls. This left
four disease features, all of which occurred at greater prevalence than
in the comparator groups. Each had different discriminatory character-
istics between the disease candidate group and comparator disease
group (see Table 2).
The disease candidate group had at least one disease feature in 95%
of cases (compared to 38% of hypertensive's and 18% of healthy con-
trols). The disease candidate group had slightly fewer features than
the HCM group but signiﬁcantly more than the hypertensive and
healthy controls (mean: 1.9 vs 2.4, 0.5 and 0.1 and median: 2 vs 2, 0
and 0 respectively, p = 0.001) see Fig. 3. No healthy subject had more
than one abnormality present. Only 6% of hypertensive patients had
≥2 features compared to 54% of the disease candidate group.
7. Discussion
This study describes an unrecognized group of patients who fall out-
side of conventional diagnostic criteria but have a collection of features
suggestive of disease akin to apical HCM. These patients have three
characteristics: ﬁrstly, characteristic ECG changes with T wave inver-
sion, deep in three quarters. Second, all had relative apical hypertrophy
not reaching conventional hypertrophy thickness criteria. Thirdly, there
was a prevalence of additional HCM imaging features (LA dilatation,
N2 cm apical cavity obliteration, scar and apical aneurysms) ap-
proaching that of classical HCM and beyond that found in healthy con-
trols or hypertension. Our referral base suggests that this cohort is not
rare—we have detected 22 such cases in less than two years at our ter-
tiary referral center (specializing in cardiomyopathy and advanced car-
diac imaging). Such patients will often receive no deﬁnitive diagnosis.
They may represent a morphologically mild or a prephenotypic variant
of apical HCM. They may share the same predisposition to morbidity as
HCM— particularly chest pain, atrial ﬁbrillation, ventricular arrhythmia
and eventual progression to overt cardiomyopathy and heart failure.
We note that of the 22 patients, 23% had a history of atrial ﬁbrillation.
Fig. 4. a) Left ventricular apical wall thickness across the groups. In healthy volunteers and hypertension, the apex is a thin structure (mean± SD=5± 1 and 6± 2). In the patients with
TWI, the apex is signiﬁcantly thicker (15±4, p b 0.001ANOVA). b) In healthy volunteers and hypertensionwall thickness universally tapers towards the apex and thus the apex:basewall
thickness ratio is always less than 0.9 (mean ± SD apex:base ratio = 0.6 ± 0.1 and 0.5 ± 0.1) unlike the disease candidate group (1.2 ± 0.3, p b 0.001).
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(18%) were veteran athletes (including the case in point, Fig. 1). While
this may be referral bias — such individuals may be more subjected to
screening and present more to healthcare services. It may be that exer-
cise over many decades, in the predisposed individual, induces myo-
pathic like changes as detected here. Some of the features seen here
(left atrial dilatation, borderline hypertrophy) occur in athletes, and
TWI in this population may presage overt cardiomyopathy develop-
ment [14].
The detection of new disease and reﬁnement of existing disease
spectra, often occurwith technological advances. Apical HCMdiagnostic
criteria have evolved according to the technology of the time: Initially,
diagnosis was made with ECG (deep TWI) [15,16] associated with the
spade like cavity obliteration described with angiography [17]. With
echocardiography camedescription of apical hypertrophy [1,18]. Subse-
quently, CMR identiﬁed apical hypertrophy missed by echocardiogra-
phy in the context of characteristic ECG changes [1,2,19,20]. Additional
features, such as apical scar and the prognostic signiﬁcance of apical an-
eurysms have recently been described [21]. In this study, the technolog-
ical driver is CMR but more related to its increased clinical use;
reﬂecting the increased awareness of physicians of missed apical HCMFig. 5. Patient ﬂow diwith TWI. Only half of gene carriers have an abnormal echocardiogram
or ECG [22] suggesting that incomplete disease expression may be very
common. The question is whether the individuals in this cohort repre-
sent incomplete disease expression by current criteria or are an extreme
of normality. Our data support the former hypothesis and suggest that
the current HCM diagnostic criteria should be modiﬁed.
A strength of this study is the two comparator groups— healthy vol-
unteers (n= 60) and hypertensive patients (n= 50). In these, no indi-
vidual had ABR N 0.9. Following Laplace's law as the radius of the
ventricle gets smaller towards the apex, as does the wall stress — the
natural tendency is for WT to thin towards the apex even when the
basal wall has hypertrophied (see Fig. 4). In hypertension for instance,
the basal WT was greater than normals but the ABR was less reﬂecting
that hypertrophy in this condition has a basal preponderance. None of
the hypertension group had TWI. Based on these two criteria alone
(ABR N 1 and TWI), our candidate disease group is entirely distinct but
the additional imaging features add certainty: both to the classiﬁcation
as a disease and in diagnostic power. The presence of N20mm of apical
obliteration was highly discriminatory with no control individual dem-
onstrating this feature. Left atrial dilatation however was common and
not speciﬁc. Apical aneurysm was an uncommon ﬁnding in patientsagram and table.
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the candidate disease group (41%) but this was also present in 8% of hy-
pertensive subjects. The pattern of scar was different — 7 out of the 9
candidate disease group had apical scar. The hypertensive patients all
had right ventricular insertion point scar in keeping with previous
studies [23].
In the patients with ABR N 1, the incidence of 0,1,2,3,4 disease fea-
tures was 5, 41, 27,18 and 9% respectively (Fig. 5). We suggest that
the presence of 2 ormore of these suggests an unequivocal disease phe-
notype (as in 54% of this cohort) whereas 0 or 1 is suspicious but may
not be diagnostic.
8. Limitations
This preliminary dataset is not comprehensive — the individuals
have not undergone: formal familial evaluation; conventional HCM
risk assessment; comprehensive investigation of myocardial mechanics
(regional function assessment, diastolic function, tagging); genotyping
and there is no serial follow-up. Further limitations of this study include
theminimal ethnic diversity in the hypertensive group, recruited from a
single geographic area. Themeasurement of relative apical hypertrophy
is difﬁcult and was performed here in an experienced tertiary center
specializing in CMR and cardiomyopathy. Therefore, the presence of ad-
ditional imaging features is important. It was not possible to index the
volume data since contemporaneous height and weights were not re-
corded. The hypertensive patients were consecutive and most were on
≤3 hypertensive agents and as such are a cohort of well controlled dis-
ease. Comparison with patients with severe hypertension would be
informative.
9. Conclusion
We identify a group of patients with a distinct phenotype not cap-
tured by existing disease classiﬁcations. This phenotype comprises
two essential criteria: ECG TWI, often deep, in the absence of other
causes and relative apical hypertrophy (ABR N 1) detected by CMR.
The presence of two or more of four minor criteria is supportive, the
minor criteria being myocardial scarring by LGE CMR, the presence of
apical aneurysm or microaneurysm, left atrial dilatation and apical cav-
ity obliteration ≥ 20 mm. We postulate that this represents an exten-
sion of the apical HCM phenotype. Further work is required to deﬁne
this entity and its prognostic signiﬁcance.
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